Five-year study of survival and tolerability of ibrutinib monotherapy in patients recruited from 37 hospitals across the UK and Ireland
-
Real-world study of ibrutinib for relapsed/refractory mantle cell lymphoma -
Mantle cell lymphoma: ibrutinib shows effect in real-world setting Real-world analysis of a UK population.
-
NICE approves two new cancer treatments New treatments for relapsed follicular lymphoma and ALK-positive advanced NSCLC
-
NICE: lenalidomide with rituximab for previously treated follicular lymphoma Technology appraisal guidance based on clinical evidence from the AUGMENT trial
-
NICE: obinutuzumab with bendamustine for rituximab-refractory follicular lymphoma The decision is open to appeal until Thursday 23 April 2020
-
R/R mantle cell lymphoma: novel CAR T-cell yields high response rate in phase 2 The treatment was associated with high rate of serious toxicities.
-
NICE votes against polatuzumab diffuse large B‑cell lymphoma The draft decision is open for public comment until 18 March 2020
-
NICE approves new ‘chemo-free’ treatment for lymphoma The draft guidance on lenalidomide with rituximab for previously treated follicular lymphoma is currently open for public comment
-
The distinct disease entities of extranodal, nodal and splenic marginal zone lymphomas are discussed separately.
-
Refractory or relapsed HL: ESHAOx displays modest activity, acceptable safety in phase 2 Korean trial finds that 33.3% showed a complete response; 38.9% a partial response.
-
Relapsed/refractory pediatric lymphoblastic lymphoma: improved survival with acute GVHD Patients with grade 2 acute GVHD had the best outcomes.
-
Aggressive B-cell lymphoma: 4 CHOP+6 rituximab cycles noninferior to 6 R-CHOP cycles in young patients Lower burden of hematological/nonhematological events with 4 cycles.
-
Aggressive B-cell NHL: pixantrone+rituximab delivers nonsignificant PFS improvement All patients had failed a prior rituximab-containing regimen.
-
R/R indolent B-cell lymphoma: durable efficacy, low late-onset toxicity with IV copanlisib 7 additional patients achieved CR at 2-year follow-up.